Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Cited by (238)

Items 101–200 of 238

1. Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques
   Nerea Zabaleta, Urja Bhatt, Cécile Hérate, Pauline Maisonnasse, Julio C. Sanmiguel, Cheikh Tacko Diop, Sofia Castore, Reynette Estelien, Dan Li, Nathalie Dereuddre‐Bosquet et al. · 2022 · Molecular Therapy
2. Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques
   Jingyou Yu, Paul V. Thomas, Michaela Sciacca, Cindy Wu, Jinyan Liu, Xuan He, Jessica J Miller, Nicole P. Hachmann, Nehalee Surve, Katherine McMahan et al. · 2023 · Cell Reports Medicine
3. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection
   Fuzhen Wang, Baoying Huang, Yao Deng, Shaobai Zhang, Xiaoqiang Liu, Lei Wang, Qianqian Liu, Li Zhao, Lin Tang, Wenling Wang et al. · 2023 · BMC Medicine
4. The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopenia
   Cheng‐Hock Toh, Guozheng Wang, Alan L. Parker · 2022 · Clinical Medicine
5. Predicting the Effects of Waning Vaccine Immunity Against COVID‐19 through High‐Resolution Agent‐Based Modeling
   Agnieszka Truszkowska, Lorenzo Zino, Sachit Butail, Emanuele Caroppo, Zhong‐Ping Jiang, Alessandro Rizzo, Maurizio Porfiri · 2022 · Advanced Theory and Simulations
6. Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol
   Roos S. G. Sablerolles, Abraham Goorhuis, Corine H. GeurtsvanKessel, Rory D. de Vries, Anke L. W. Huckriede, Marion Koopmans, Melvin Lafeber, Douwe F. Postma, Debbie van Baarle, Leo G. Visser et al. · 2021 · Frontiers in Immunology
7. The development and application of pseudoviruses: assessment of SARS-CoV-2 pseudoviruses
   Conglian Tan, Nian Wang, Shanshan Deng, Xiaoheng Wu, Changwu Yue, Xu Jia, Yuhong Lyu · 2023 · PeerJ
8. The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis
   Danielle Soares de Oliveira Daian e Silva, Flávio Guimarães da Fonseca · 2021 · Vaccines
9. Human adenovirus type 26 basic biology and its usage as vaccine vector
   Dragomira Majhen · 2022 · Reviews in Medical Virology
10. Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters
    Rafael Rahal Guaragna Machado, Jordyn L. Walker, Dionna Scharton, Grace H. Rafael, Brooke M. Mitchell, Rachel A. Reyna, William Marciel de Souza, Jianying Liu, David Hughes Walker, Jessica A. Plante et al. · 2023 · Nature Communications
11. Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV
    Myrthe L. Verburgh, Anders C. Boyd, Ferdinand W.N.M. Wit, Maarten F. Schim van der Loeff, Marc van der Valk, Margreet E. Bakker, Neeltje A. Kootstra, Lia van der Hoek, Peter Reiss · 2021 · The Journal of Infectious Diseases
12. Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial
    Youyi Fong, Adrian B. McDermott, David C. Benkeser, Sanne Roels, Daniel J Stieh, An Vandebosch, Mathieu Le Gars, Griet A. Van Roey, Christopher R. Houchens, Karen A. O. Martins et al. · 2022 · medRxiv
13. Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany
    Alex Dulovic, Barbora Kessel, Manuela Harries, Matthias Becker, Julia Ortmann, Johanna Griesbaum, Jennifer Juengling, Daniel Junker, Pilar Hernández, Daniela Gornyk et al. · 2022 · Frontiers in Immunology
14. Longitudinal Serological Surveillance for COVID-19 Antibodies after Infection and Vaccination
    Christopher A. McGee, Min Shi, John S. House, Anna Drude, Gladys Gonzalez, Negin P. Martin, Shih‐Heng Chen, Heidi Rogers, Alexander Njunge, Xiomara Hodge et al. · 2022 · Microbiology Spectrum
15. Vaccine hesitancy promotes emergence of new SARS-CoV-2 variants
    Shuanglin Jing, Russell Milne, Hao Wang A, Ling Xue · 2023 · Journal of Theoretical Biology
16. Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells
    Robert G. E. Krause, Thandeka Moyo-Gwete, Simone I. Richardson, Zanele Makhado, Nelia P. Manamela, Tandile Hermanus, Nonhlanhla N. Mkhize, Roanne Keeton, Ntombi Benede, Mathilda Mennen et al. · 2023 · npj Vaccines
17. Covid-19 Rates by Time since Vaccination during Delta Variant Predominance
    Gabriela Paz‐Bailey, Maya Sternberg, Kiersten J. Kugeler, Brooke Hoots, Avnika B. Amin, Amelia G. Johnson, Bree Barbeau, Nagla S. Bayoumi, Daniel Bertolino, Rachelle Boulton et al. · 2021 · NEJM Evidence
18. Vaccines for Respiratory Viruses—COVID and Beyond
    Kalpana Rajanala, Arun Upadhyay · 2024 · Vaccines
19. Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial
    Nina Hertoghs, Sanne Roels, Matthias Brückner, JERALD C. SADOFF, Barbara L. Banbury, Nicholas K. Akers, Bryan Howie, Harlan S. Robins, Griet A. Van Roey, Jeroen T. B. M. Tolboom et al. · 2025 · EBioMedicine
20. A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization
    Sameer-ul-Salam Mattoo, Jinjong Myoung · 2021 · Journal of Microbiology and Biotechnology
21. Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease
    Devendra Bansal, Jazeel Abdulmajeed, Esraa Yassin, Maha Hammam M. A. Al-Shamali, Soha Shawqi Albayat, Sayed M. Himatt, Farhan Sachal Cyprian, Tawanda Chivese, Jesha Mohammedali Mundodan, Hayat Khogali et al. · 2022 · Vaccines
22. Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
    Shant H. Mahrokhian, Lisa H. Tostanoski, Catherine Jacob-Dolan, Roland C. Zahn, Frank Wegmann, Katherine McMahan, Jingyou Yu, Makda S. Gebre, Esther Apraku Bondzie, Huahua Wan et al. · 2022 · npj Vaccines
23. Should Breakthrough SARS-CoV-2 Infection Affect Our Confidence in the COVID-19 Vaccines?
    Emmanuel Lamptey · 2021 · Infection and Chemotherapy
24. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers
    Maria Giaele Infantino, Mariangela Manfredi, Lorenzo Stacchini, Claudia Cosma, Valentina Grossi, Barbara Lari, Edda Russo, Amedeo Amedei, Maurizio Benucci, Francesca Veneziani et al. · 2022 · Clinical Chemistry and Laboratory Medicine (CCLM)
25. An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity
    Emma Chang-Rabley, Menno C. van Zelm, Emily Ricotta, Emily S.J. Edwards · 2024 · Vaccines
26. A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants
    Marwa Alhashimi, Ekramy E. Sayedahmed, Ahmed Elkashif, Shubhada K. Chothe, Wen-Chien Wang, Muralimanohara S. T. Murala, Vivek Gairola, Nobuko Wakamatsu, Abhinay Gontu, Santhamani Ramasamy et al. · 2025 · npj Vaccines
27. Immunological memory to vaccines
    Shane Crotty · 2026 · Immunity
28. Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study
    Juan Carlos Gómez de la Torre, José Alonso Cáceres-DelAguila, Cecilia Muro-Rojo, Nathalia De La Cruz-Escurra, Cesar Augusto Copaja Corzo, Miguel Hueda-Zavaleta, Daniella Arenas Siles, Vicente Aleixandre Benites-Zapata · 2022 · Tropical Medicine and Infectious Disease
29. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination
    Fuzhen Wang, Baoying Huang, Huakun Lv, Lizhong Feng, Weihong Ren, Xiaoqi Wang, Lin Tang, Qianqian Liu, Dan Wu, Hui Zheng et al. · 2022 · Frontiers in Immunology
30. Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
    Chiara Agrati, Concetta Castilletti, Simone Battella, Eleonora Cimini, Giulia Matusali, Andrea Sommella, Alessandra Sacchi, Francesca Colavita, Alessandra Maria Contino, Veronica Bordoni et al. · 2022 · npj Vaccines
31. Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination
    Antonella Zizza, Raffaella Sedile, Francesco Bagordo, Alessandra Panìco, Marcello Guido, Tiziana Grassi, Federico Banchelli, Pierfrancesco Grima · 2023 · Vaccines
32. Humoral and cellular immunity against diverse SARS-CoV-2 variants
    Changxu Chen, Xin Wang, Zeli Zhang · 2023 · Journal of genetics and genomics/Journal of Genetics and Genomics
33. Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
    Puja Jaishwal, Kisalay Jha, Satarudra Prakash Singh · 2024 · International Journal of Biological Macromolecules
34. Study of humoral and cellular immunity in vaccinated with mRNA‐1273
    Juan Francisco Gutiérrez‐Bautista, Miguel Ángel López‐Nevot, Esther Gómez-Vicente, Trinidad Quesada, Eva María Marín, Ana Isabel Enríquez Rodríguez, Ana Isabel Enríquez Rodríguez, Javier Rodríguez‐Granger, Fernando Cobo, Antonio Sampedro · 2022 · Apmis
35. Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine
    Tiziana Grassi, Giambattista Lobreglio, Alessandra Panìco, Chiara Rosato, Antonella Zizza, Roberta Lazzari, Michele Chicone, Floriano Indino, Francesco Bagordo · 2022 · Vaccines
36. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
    Eun Kim, Muhammad S. Khan, Alessandro Ferrari, Shaohua Huang, Josè Camilla Sammartino, Elena Percivalle, Thomas W. Kenniston, Irene Cassaniti, Fausto Baldanti, Andrea A. Gambotto · 2023 · Microbiology Spectrum
37. Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates
    Matthew Gagné, Barbara J. Flynn, Shayne F. Andrew, Dillon R. Flebbe, Anna Mychalowych, Evan Lamb, Meredith E. Davis-Gardner, Matthew R. Burnett, Leonid Serebryannyy, Bob C. Lin et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
38. A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant
    Albert To, Teri Ann S. Wong, Michael M. Lieberman, Karen Sue Thompson, Aquena H. Ball, Laurent Pessaint, Jack J. Greenhouse, Nisrine Daham, Anthony Cook, Brandon Narvaez et al. · 2022 · ACS Infectious Diseases
39. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN
    Jingyou Yu, Paul V. Thomas, Katherine McMahan, Catherine Jacob-Dolan, Jinyan Liu, Xuan He, David L. Hope, Elizabeth J. Martinez, Wei‐Hung Chen, Michaela Sciacca et al. · 2022 · Science Advances
40. Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
    Αναστασία Παπαδοπούλου, Fani Stavridou, Maria Giannaki, Kiriaki Paschoudi, Fani M. Chatzopoulou, Eleni Gavriilaki, Grigorios Georgolopoulos, Αchilles Anagnostopoulos, Evangelia Yannaki · 2022 · Heliyon
41. Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine
    Zhifei Chen, Fangqin Xie, Hairong Zhang, Li Dong, Suhan Zhang, Mengping Zhang, Junrong Li, Jianfeng Xie, Lina Zhang, Xiuhui Yang et al. · 2025 · Frontiers in Public Health
42. COVID-19 Vaccines—All You Want to Know
    Akira A. Shishido, Ashley H. Barnes, Shivakumar Narayanan, Joel V. Chua · 2023 · Seminars in Respiratory and Critical Care Medicine
43. Neutralizing antibody responses to SARS-CoV-2 variants after COVID-19 vaccination and boosters
    Kabita Adhikari, Subhash Chandra Verma · 2025 · Vaccine X
44. Prolonged SARS-CoV-2 T Cell Responses in a Vaccinated COVID-19-Naive Population
    Vassiliki Ch. Pitiriga, Myrto Papamentzelopoulou, Kanella E. Konstantinakou, Irene V. Vasileiou, Alexandros D. Konstantinidis, Natalia I. Spyrou, Athanasios Tsakris · 2024 · Vaccines
45. CD81 fusion alters SARS-CoV-2 Spike trafficking
    Allaura S. Cone, Yijun Zhou, Ryan P. McNamara, Anthony B. Eason, Gabriel F. Arias, Justin T. Landis, Kyle Shifflett, Meredith G. Chambers, Runjie Yuan, Smaranda Willcox et al. · 2024 · mBio
46. Kinetics and persistence of anti‐SARS‐CoV‐2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort
    Lara Šošić, Marta Paolucci, Agathe Duda, Fabio Hasler, Senta M. Walton, Thomas M. Kündig, Pål Johansen · 2021 · Immunity Inflammation and Disease
47. Review of Immunologic Manifestations of COVID-19 Infection and Vaccination
    Valeriya Pozdnyakova, Brittany Weber, Susan C. Cheng, Joseph E. Ebinger · 2022 · Cardiology Clinics
48. Lessons from a large-scale COVID-19 vaccine trial
    Ranjeet Singh Mahla, Lynn B. Dustin · 2022 · Journal of Clinical Investigation
49. Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
    Niels Adriaenssens, Béatrice Scholtes, Robin Bruyndonckx, Pauline Van Ngoc, Jan Yvan Jos Verbakel, An De Sutter, Stefan Heytens, Ann Van den Bruel, Isabelle Desombere, Pierre Van Damme et al. · 2022 · BMJ Open
50. Persistent humoral and CD4+ TH cell immunity after mild SARS-COV-2 infection—The CoNAN long-term study
    Clara Schnizer, Nico Andreas, Wolfgang Vivas, Thomas Kamradt, Michael Baier, Michael Kiehntopf, Stefan Glöckner, André Scherag, Bettina Löffler, Steffi Kolanos et al. · 2023 · Frontiers in Immunology
51. Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
    Keith J. Chappell, Francesca L. Mordant, Alberto Anastacio Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Danushka K. Wijesundara, Julia A. Lackenby, Paul Griffin, Jillian K. Bennet et al. · 2023 · EBioMedicine
52. Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
    Aiquan Chang, Jingyou Yu · 2022 · Viruses
53. Case of reactive sacroiliitis possibly induced by an mRNA coronavirus disease vaccine
    Nicolas Roux, Sophie Poussing, F. Maurier · 2022 · BMJ Case Reports
54. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
    Matthew Gagné, Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, Danielle A. Wagner, Shayne F. Andrew, John-Paul M. Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T. Nurmukhambetova et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
55. Assessing T-Cell Immunity in Kidney Transplant Recipients with Absent Antibody Production after a 3rd Dose of the mRNA-1273 Vaccine
    Maria Giaele Infantino, Aris Tsalouchos, Edda Russo, Selene Laudicina, Valentina Grossi, Barbara Lari, Maurizio Benucci, Lorenzo Stacchini, Amedeo Amedei, Patrizia Casprini et al. · 2022 · International Journal of Molecular Sciences
56. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
    Thandeka Moyo-Gwete, Simone I. Richardson, Roanne Keeton, Tandile Hermanus, Holly Spencer, Nelia P. Manamela, Frances Ayres, Zanele Makhado, Thopisang P. Motlou, Marius Belmondo Tincho et al. · 2023 · PLoS Pathogens
57. Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study
    Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende‐Zuma, Azwidihwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie et al. · 2024 · PLOS Global Public Health
58. Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines—Effectiveness in Delta Variant Breakthrough Infections
    Gema Fernández‐Rivas, Jaume Barallat, Bibiana Quirant‐Sánchez, Victoria González, María Doladé, Eva María Martínez-Cáceres, Monica Piña, Joan Matlló, Ignacio Blanco, Père-Joan Cardona · 2022 · Viruses
59. Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It
    Zhipeng Yan, Ming Yang, Ching‐Lung Lai · 2022 · Frontiers in Drug Discovery
60. Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection
    Panagiotis Theodorou Diamantopoulos, Christina‐Nefeli Kontandreopoulou, Christos Stafylidis, Dimitra Vlachopoulou, Nefeli Giannakopoulou, Maria Vardaka, Anthi Mpouhla, Eleni Variami, Athanasios G. Galanopoulos, Vasiliki Pappa et al. · 2022 · Annals of Hematology
61. RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease
    Chandrasekharan Rajalekshmi Dhanya, Aswathy Shailaja, Aarcha Shanmugha Mary, Sumodan Padikkala Kandiyil, Ambili Savithri, Senthil Kumar Vishnu, Jayakrishnan Therthala Veettil, Jiji Joseph Vandanamthadathil, Maya Madhavan · 2022 · Pathogens
62. B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S
    Catherine Jacob-Dolan, Michelle A. Lifton, Olivia C. Powers, Jessica J Miller, Nicole P. Hachmann, Mya L. Vu, Nehalee Surve, Camille R. Mazurek, Jana L. Fisher, Stefanie L. Rodrigues et al. · 2024 · iScience
63. Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa
    Salim S. Abdool Karim, Cheryl Baxter · 2021 · Transactions of the Royal Society of South Africa
64. Neutralization assays for SARS-CoV-2
    Labanya Mukhopadhyay, Nivedita Gupta, Pragya Dhruv Yadav, Neeraj Aggarwal · 2022 · The Indian Journal of Medical Research
65. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study
    Xiaoqi Wang, Yao Liang Deng, Li Zhao, Lei Wang, Zhenwang Fu, Lin Tang, Fei Ye, Qianqian Liu, Wenling Wang, Siquan Wang et al. · 2022 · Vaccine
66. Immunological heterogeneity informs estimation of the durability of vaccine protection
    Matthieu Domenech de Cellès, Anabelle Wong, Laura Andrea Barrero Guevara, Pejman Rohani · 2022 · Journal of The Royal Society Interface
67. Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
    Hakjun Hyun, Min Joo Choi, Jung Yeon Heo, Yu Bin Seo, Eliel Nham, Jin Gu Yoon, Hye Seong, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim et al. · 2022 · Journal of Korean Medical Science
68. Placental Transfer Efficiency of Neutralizing Antibodies on SARS-CoV-2 Vaccination before and after Pregnancy in Mexican Women
    Rebeca Martínez-Quezada, Carlos Emilio Miguel-Rodríguez, Tito Ramírez-Lozada, Omar Esteban Valencia-Ledezma, Gustavo Acosta‐Altamirano · 2024 · International Journal of Molecular Sciences
69. Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
    Prasad Suryakant Kulkarni, Chandrasekaran Padmapriyadarshini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, BS Garg, Nithya Gogtay, Muralidhar Tambe, Sanjay Kewalchand Lalwani et al. · 2024 · Human Vaccines & Immunotherapeutics
70. Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study
    Vicky Cárdenas, Mathieu Le Gars, Carla Truyers, Javier Ruiz‐Guiñazú, Frank Struyf, Alicia Colfer, Marc J. M. Bonten, Alberto Manuel Borobia, Emil Christian Reisinger, Ingrid M. C. Kamerling et al. · 2024 · Vaccine
71. Immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population
    Yao Tian, Xiaohong Zhang, Shengcai Mu, Yana Guo, Xiuyang Xu, Junfeng Huo, Zhiyun Wei, Ling Liu, Xiaoqing Li, Hong Li et al. · 2022 · Expert Review of Vaccines
72. A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response
    Elliot Campbell, Julie Dobkin, Louis Osorio, Afsal Kolloli, Santhamani Ramasamy, Ranjeet Kumar, Derek B. Sant’Angelo, Selvakumar Subbian, Lisa K. Denzin, Stephen Anderson · 2023 · Vaccines
73. Cryptic Transmission of the Delta Variant AY.3 Sublineage of SARS-CoV-2 among Fully Vaccinated Patients on an Inpatient Ward
    Katherine D. Linsenmeyer, Kalpana Gupta, Rebecca Madjarov, Michael E. Charness · 2021 · medRxiv
74. Comment on “Oral lichen planus following the administration of vector based COVID‐19 vaccine (Ad26.COV2.S)”. Authors' reply
    Matthias Troeltzsch, Ronald Berndt, Markus Troeltzsch · 2021 · Oral Diseases
75. Vaccine effectiveness of JCOVDEN single-dose against COVID-19 hospitalisation in Europe: An id.DRIVE test-negative case-control study
    Chloé Wyndham-Thomas, E. Claire Newbern, Ainara Mira‐Iglesias, Akshat Dwivedi, Alejandro Orrico‐Sánchez, Andrés Antón, Charlotte Martin, Giancarlo Icardi, Irma Casas, Kok Yew Ngew et al. · 2025 · Journal of Infection and Public Health
76. Humoral and Cellular Immunity to Severe Acute Respiratory Syndrome Coronavirus-2 Vaccination in Patients with Sarcoidosis
    Ersan Atahan, Buket Çalışkaner Öztürk, Rüveyda Akçin, Suat Sarıbaş, Bekir Sami Kocazeybek · 2022 · Balkan Medical Journal
77. Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy
    Mohamad Hamad, Dana M.H. AlKhamach, Lujain Majed Alsayadi, Sirin Abdulkafi Sarhan, Balsam Qubais Saeed, Marina Sokóvić, Taïbi Ben Hadda, Sameh S. M. Soliman · 2023 · Viral Immunology
78. Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19
    Jialu Feng, Wen-Juan Wang, Pengfei Jin, Hui Zheng, Lairun Jin, Xin Xia, Xiaoyin Zhang, Zhuo-Pei Li, Jingxin Li, Fengcai Zhu · 2023 · Human Vaccines & Immunotherapeutics
79. Deisolation in the Healthcare Setting Following Recent COVID-19 Infection
    Samuel Baumgart, Aidan R McLachlan, Hayden Kenny, Genevieve L. McKew, Susan Maddocks, Wen Chen, Jen Kok · 2024 · Viruses
80. Review of Immunologic Manifestations of COVID-19 Infection and Vaccination
    Valeriya Pozdnyakova, Brittany Weber, Susan C. Cheng, Joseph E. Ebinger · 2024 · Rheumatic Disease Clinics of North America
81. COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response
    Sherry Tong, Sean M. Litwin, Elissa S. Epel, Jue Lin, Stacy S. Drury, Frederick M. Hecht, James E. Robinson, Aric A. Prather, Elizabeth B. Norton · 2025 · Vaccine
82. Immune responses to SARS-CoV-2 infection and COVID-19 vaccines
    Basista Rabina Sharma, Ravindra P. Veeranna · 2022 · Exploration of Immunology
83. Effect of vaccination on the case fatality rate for COVID-19 infections 2020–2021: multivariate modelling of data from the US Department of Veterans Affairs
    Glen H. Murata, Allison E. Murata, Douglas Jay Perkins, Heather M. Campbell, Jenny T. Mao, Brent Wagner, Benjamin H. McMahon, Curt H. Hagedorn · 2022 · BMJ Open
84. Humoral Immune Responses following COVID-19 Vaccinations among Adults in Tanzania
    Muhammad Bakari, Said Aboud, Mabula Joseph Kasubi, Bruno P. Mmbando, Nyanda Elias Ntinginya, Aifello W. Sichalwe, Omary Ubuguyu, Alex Sifaeli Magesa, Nancy Ladislaus Rutananukwa, Helmut A. Nyawale et al. · 2023 · Vaccines
85. Planning for the emergence of vaccine-resistant SARS-CoV-2: addressing revaccination delivery bottlenecks
    John Willan, Katie JM Jeffery, Lorenz Kemper, Robbie Scott, Andrew John King, Claire Bayntun · 2021 · Journal of the Royal Society of Medicine
86. Pre-Clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-2
    Mikhail Novikov, Mohadeseh Hasanpourghadi, Robert Ambrose, Arezki Chekaoui, Dakota Newman, Wynetta Giles‐Davis, Zhiquan Xiang, Xiang Zhou, Hildegund C.J. Ertl · 2022 · SSRN Electronic Journal
87. Kinetics and Factors Associated With 12-Month Persistence of Neutralizing Antibody Induced by Two Inactivated COVID-19 Vaccines
    Fu-zhen Wang, Baoying Huang, Huakun Lv, Lizhong Feng, Weihong Ren, Xiaoqi Wang, Lin Tang, Qianqian Liu, Dan Wu, Hui Zheng et al. · 2022 · SSRN Electronic Journal
88. Persistent Maintenance of Atypical Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response
    Jernej Pušnik, Julia König, Karola Mai, Enrico Richter, Jasmin Zorn, Hannah Proksch, Bianca Schulte, Galit Alter, Hendrik Streeck · 2022 · SSRN Electronic Journal
89. Effectiveness of Vaccination Against SARS-CoV-2 Omicron Variant Infection, Symptomatic Disease, and Hospitalisation: A Systematic Review and Meta-Analysis
    Angela Meggiolaro, Monica Sañé Schepisi, Sara Farina, Carolina Castagna, Alessia Mammone, Andrea Siddu, Paola Stefanelli, Stefania Boccia, Giovanni Rezza · 2022 · SSRN Electronic Journal
90. Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial
    Alex R. Luedtke, Youyi Fong, Lars W. P. van der Laan, Fei Heng, Ying Huang, Yiwen Lu, Chenchen Yu, Lindsay N. Carpp, Sanne Roels, Mathieu Le Gars et al. · 2025 · iScience
91. Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2
    Ana López-Gomez, Irene Real-Arévalo, Elsa Mayol, Jana Ausio Cendra, Diego Laxalde-Fernández, Pablo Nogales‐Altozano, Benigno Rivas-Pardo, Beatriz Amorós-Pérez, Beatriz Martín-Adrados, Ignacio Juárez et al. · 2026 · Scientific Reports
92. Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial
    Vaneshree Govender, Tarylee Reddy, Pholo W. Maenetje, Trevor Beattie, Tania Adonis, Tanya Nielson, Jayajothi Moodley, John Mdluli, Aruna Bhoola, Stacey Angelo et al. · 2026 · The Lancet HIV
93. A genetically engineered, stem-cell-derived cellular vaccine
    Amanda Cooper, Adam Sidaway, Abishek Chandrashekar, Elizabeth Latta, Krishnendu Chakraborty, Jingyou Yu, Katherine McMahan, Victoria M. Giffin, Cordelia Manickam, Kyle W. Kroll et al. · 2022 · Cell Reports Medicine
94. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting
    Gaurav Batra, Deepika Rathna Murugesan, Sreevatsan Raghavan, Souvick Chattopadhyay, Farha Mehdi, Ayushi, Mudita Gosain, Savita Singh, Soon Jyoti Das, Suprit Deshpande et al. · 2023 · International Journal of Microbiology Research
95. Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population
    Yao Tian, Yana Guo, Xiuyang Xu, Xiaohong Zhang, Shengcai Mu, Junfeng Huo, Zhiyun Wei, Ling Liu, Xiaoqing Li, Hong Li et al. · 2023 · Vaccine
96. Current Development of Data Resources and Bioinformatics Tools for Anticoronavirus Peptide
    Bowen Li, Min Li, Chunying Lu, Yifei Wu, Heng Chen, Bifang He · 2024 · Current Medicinal Chemistry
97. Dynamics of SARS-CoV-2 IgG antibodies and neutralising antibodies in rheumatic and musculoskeletal diseases patients with COVID-19
    Qi Wang, Yunjuan Wu, Lingyun Wu, Chengyin Lu, Yao Ke, Yanyan Wang, Lei Gu, Youxuan Shen, Wenfeng Tan · 2023 · Clinical and Experimental Rheumatology
98. Correlates of COVID-19 vaccine uptake among the forcibly displaced: evidence from Libya
    Meshack Achore · 2024 · Archives of Public Health
99. A Candidate Systematic Approach to Investigate ROBUST,SUPERIORLY BROAD, IMMUNE RESPONSE, 8 Months Following Severe COVID Infection, ICU Hospitalization, Viral Clearance, Rehabilitation, and Recovery with No Vaccine Booster Dose or Reinfection
    Girish Jayant Kotwal · 2021 · Journal of Virology Research & Reports
100. Comparative analysis of post-vaccination anti-spike IgG antibodies in old Nursing Home Residents and in middle-aged Healthcare workers
     Hélène Jeulin, D. Craus, Carlos Labat, Athanasios Benetos · 2021 · medRxiv